Friday, 13 Sep 2019

You are here

Risk of Sepsis or Death Lower with Biologics in Rheumatoid Arthritis

Researchers from Germany have analyzed their large prospective rheumatoid arthritis (RA) registry to address whether being on biologic therapies leads to poorer outcomes - namely sepsis or death, following a serious infection (SIE).

They examined the outcomes of SIEs in 947 RA patients enrolled in the German biologics RABBIT registry, specifically noting the following outcomes (1) recovery, (2) sepsis following SIE (≤30 days), or (3) death after SI, without known sepsis (occurring in ≤90 days). 

Sepsis within 30 days of an SIE was reported in 14.2% of patients and 85 of these were fatal.  Death (without sepsis) occurred in 5.6% of patients within 90 days of SIE.  

The adjusted risk of developing sepsis increased with age and was higher in patients with chronic renal disease.

Patients treated with biologic DMARDs (bDMARDs) at the time of SIE, had a lower risk of death than those with conventional synthetic (cs)DMARDs (OR: 0.56, 95% CI 0.38 - 0.81).

Risk factors of fatal SIE were higher age, use of glucocorticoids at higher doses and heart failure.

Patients treated with bDMARDs and those with better physical function had a significantly lower mortality risk.

These findings suggest that better control of inflammation may limit the mortal risks imposed by a serious infection in treated RA patients. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.